Recent advance in clinical drug therapy for Alzheimer's disease
10.3760/cma.j.cn115354-20230228-00107
- VernacularTitle:阿尔茨海默病药物临床研究进展
- Author:
Shang YI
1
;
Henghui TAN
;
Runtong LI
;
Zijun LIAO
;
Xin WEN
;
Xiaoya GAO
Author Information
1. 南方医科大学珠江医院神经内科，广州 510282
- Keywords:
Alzheimer's disease;
Beta-amyloid protein;
Tau protein;
Targeted drug;
Clinical trial
- From:
Chinese Journal of Neuromedicine
2023;22(8):849-855
- CountryChina
- Language:Chinese
-
Abstract:
Alzheimer's disease (AD) is the first degenerative disease of the nervous system, but no drugs have been found to reverse AD progression. Starting from 2 major pathogenesis of AD, namely amyloid beta (Aβ) cascade and Tau protein, this study systematically reviews anti-Aβ or Tau protein AD new drugs that have entered clinical research; this study also expounds their clinical trial findings and mechanisms, and analyzes the reasons for their success or failure to provide a theoretical basis for AD drug exploitation.
